NASDAQ:SNCA

Seneca Biopharma (SNCA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$5.51
$6.45
50-Day Range
$1.39
$10.25
52-Week Range
$0.50
$2.67
Volume
458,802 shs
Average Volume
3.78 million shs
Market Capitalization
$109.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SNCA stock logo

About Seneca Biopharma Stock (NASDAQ:SNCA)

Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

SNCA Stock News Headlines

See this before next week's Fed meeting
See this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.)
Seneca Foods Corp Class A
West Seneca West Senior High School
Seneca High School
See More Headlines
Receive SNCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seneca Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SNCA
CIK
N/A
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Net Income
$-8,350,000.00
Net Margins
-230.34%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Price / Sales
10,982.96
Book Value
$1.33 per share

Miscellaneous

Free Float
N/A
Market Cap
$109.83 million
Optionable
Not Optionable
Beta
1.83
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Kenneth C. Carter (Age 61)
    Exec. Chairman
    Comp: $492.5k
  • Mr. Dane R. Saglio (Age 63)
    Principal Exec. & Accounting Officer
    Comp: $435.75k
  • Dr. Karl Y. Johe (Age 61)
    Co-Founder
  • Dr. David P. Recker FACR (Age 63)
    M.D., FACP, Chief Medical Officer

SNCA Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Seneca Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seneca Biopharma investors own include OpGen (OPGN), Sorrento Therapeutics (SRNE), AIM ImmunoTech (AIM), DURECT (DRRX), Nabriva Therapeutics (NBRV), OPKO Health (OPK), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Fulcrum Therapeutics (FULC) and iBio (IBIO).

This page (NASDAQ:SNCA) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners